AU Stock MarketDetailed Quotes
SNT Syntara Ltd
- 0.046
- +0.004+9.52%
20min DelayMarket Closed Nov 22 15:33 AET
63.16MMarket Cap-2875P/E (Static)
0.047High0.044Low3.51MVolume0.047Open0.042Pre Close160.38KTurnover0.05852wk High0.48%Turnover Ratio1.37BShares0.01452wk Low-0.016EPS TTM33.61MFloat Cap0.058Historical HighLossP/E (Static)730.76MShs Float0.014Historical Low-0.016EPS LYR7.14%Amplitude--Dividend TTM15.33P/B1Lot Size--Div YieldTTM
About Syntara Ltd Company
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.
Company Profile
SymbolSNT
Company NameSyntara Ltd
Founded1998
MarketASX
Employees21
Fiscal Year Ends06-30
Address20 Rodborough Road Unit 2
CitySydney
CountryAustralia
Zip Code2086
Phone+61 287601480
Websitehttps://www.syntaratx.com.au
Share RegistryBOARDROOM PTY LIMITED
LEVEL 8, 210 GEORGE STREET, SYDNEY, NSW, AUSTRALIA, 2000
(02) 9290 9600
Company Executives
- Name
- Position
- Salary
- Gary Jonathan Phillips
- Executive Director and Chief Executive Officer
- --
- David Morris McGarvey
- Chief Financial Officer and Company Secretary
- --
- Jana Baskar
- Chief Medical Officer
- --
- Kathleen Mary Metters
- Non-Executive Chairman of the Board
- --
- Simon Green
- Director
- --
- Hashan De Silva
- Director
- --
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
% Chg
No Data